FUNDING OPPORTUNITIES

FEDERAL FUNDING AGENCIES
National Institutes of Health (NIH)

Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01) (PA-12-024)
Office of Behavioral and Social Science Research
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Mental Health
National Institute of Nursing Research
Application Receipt Date(s): Multiple dates, see announcement.

The NEI Mentored Clinical Scientist Development Program Award (K12) (PAR-12-002)
National Eye Institute
Application Receipt Date(s): May 14, 2012; 2013; and 2014

Limited Competition: Framework Programs for Global Health Innovation (D43) (PAR-12-003)
John E. Fogarty International Center
Application Receipt Date(s): December 15, 2011, December 14, 2012

Nuclear Receptor Signaling Atlas (NURSA): Hub (U24) (RFA-DK-11-017)
National Institute of Diabetes and Digestive and Kidney Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): March 07, 2012

NIDDK Interconnectivity Network Coordinating Unit (U24) (RFA-DK-11-030)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): March 15, 2012

Professional Society Programs to Promote Diversity (R25) (RFA-DK-11-014)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): December 22, 2011

**NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22)**
(PAR-12-004)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): Multiple dates, see announcement.

**National Cancer Institute Program Project (P01) Applications**
(PAR-12-005)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.

**SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44)**
(RFA-CA-12-001)
National Cancer Institute
Application Receipt Date(s): December 28, 2011; March 27, 2012

**Molecular Imaging of the Lung- Phase 1 (R01)**
(RFA-HL-12-036)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): February 01, 2012

**Diabetes Research Training for Behavioral Scientists (T32)**
(RFA-DK-11-027)
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Nursing Research
Application Receipt Date(s): March 02, 2012

**Career Development Programs in Diabetes Research for Behavioral Scientists (K12)**
(RFA-DK-11-028)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): March 02, 2012

**Cardiovascular Research Network (CVRN) Limited Competition (U54)**
(RFA-HL-13-004)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): February 29, 2012

**Targeted Analyses of Jackson Heart Study Data (R01)**
(RFA-HL-13-007)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): February 28, 2012

**Academic Research Enhancement Award (Parent R15)**
(PA-12-006)
National Institutes of Health
National Center for Complementary and Alternative Medicine
National Cancer Institute
National Center for Research Resources
National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism  
National Institute of Allergy and Infectious Diseases  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
National Institute of Biomedical Imaging and Bioengineering  
*Eunice Kennedy Shriver* National Institute of Child Health and Human Development  
National Institute on Drug Abuse  
National Institute on Deafness and Other Communication Disorders  
National Institute of Dental and Craniofacial Research  
National Institute of Diabetes and Digestive and Kidney Diseases  
National Institute of Environmental Health Sciences  
National Institute of General Medical Sciences  
National Institute of Mental Health  
National Institute of Neurological Disorders and Stroke  
National Institute of Nursing Research  
National Library of Medicine  
Application Receipt Date(s): Multiple dates, see announcement.

**NIH Director's Early Independence Awards (DP5)**  
(RFA-RM-11-007)  
NIH Roadmap Initiatives  
Application Receipt Date(s): January 30, 2012

**Innovative Pilot Studies of Novel Mechanism of Action Compounds for Treating Psychiatric Disorders (U01)**  
(PAR-12-007)  
National Institute of Mental Health  
Application Receipt Date(s): Multiple dates, see announcement.

**Lasker Clinical Research Scholars Program (Si2)**  
(RFA-OD-12-001)  
National Institutes of Health  
National Cancer Institute  
National Human Genome Research Institute  
National Heart, Lung, and Blood Institute  
National Institute on Alcohol Abuse and Alcoholism  
*Eunice Kennedy Shriver* National Institute of Child Health and Human Development  
National Institute on Drug Abuse  
National Institute of Dental and Craniofacial Research  
National Institute of Mental Health  
National Institute of Neurological Disorders and Stroke  
National Institute of Nursing Research  
Application Receipt Date(s): January 24, 2012

**Technology Development to Enable Large Scale Metabolomics Analyses (R01)**  
(RFA-RM-11-019)  
NIH Roadmap Initiatives  
Application Receipt Date(s): January 31, 2012

**Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials (R01)**  
(PA-12-013)  
National Cancer Institute  
Application Receipt Date(s): Multiple dates, see announcement.

**Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials (R21)**
Practical Interventions to Improve Medication Adherence in Primary Care (R01)  
(PA-12-022)  
Office of Behavioral and Social Science Research  
National Center for Complementary and Alternative Medicine  
National Cancer Institute  
National Eye Institute  
National Heart, Lung, and Blood Institute  
National Institute on Aging  
National Institute on Deafness and Other Communication Disorders  
National Institute of Diabetes and Digestive and Kidney Diseases  
National Institute of Mental Health  
National Institute of Nursing Research  
Application Receipt Date(s): Multiple dates, see announcement.

Practical Interventions to Improve Medication Adherence in Primary Care (R21)  
(PA-12-023)  
Office of Behavioral and Social Science Research  
National Center for Complementary and Alternative Medicine  
National Eye Institute  
National Heart, Lung, and Blood Institute  
National Institute on Aging  
National Institute on Deafness and Other Communication Disorders  
National Institute of Mental Health  
National Institute of Nursing Research  
Application Receipt Date(s): Multiple dates, see announcement.

NIA MSTEM: Advancing Diversity in Aging Research (ADAR) through Undergraduate Education (R25)  
(PAR-12-016)  
National Institute on Aging  
Application Receipt Date(s): Multiple dates, see announcement.

Shared Instrumentation Grant Program (S10)  
(PAR-12-017)  
National Center for Research Resources  
Application Receipt Date(s): March 21, 2012

NIDDK Mentored Research Scientist Development Award (K01)  
(PAR-12-020)  
National Institute of Diabetes and Digestive and Kidney Diseases  
Application Receipt Date(s): Multiple dates, see announcement.

Midcareer Investigator Award in Mouse Pathobiology and Comprehensive Phenotyping Research (K26)  
(PAR-12-021)  
National Center for Research Resources  
Application Receipt Date(s): January 07, 2015

Expanding the Encyclopedia of DNA Elements (ENCODE) in the Human and Model Organisms (U54)  
(RFA-HG-11-024)  
National Human Genome Research Institute  
Application Receipt Date(s): December 21, 2011
Computational Analysis of the Encyclopedia of DNA Elements (ENCODE) Data (U01)
(RFA-HG-11-025)
National Human Genome Research Institute
Application Receipt Date(s): December 21, 2011

Data Analysis and Coordination Center for the Encyclopedia of DNA Elements (ENCODE) (U41)
(RFA-HG-11-026)
National Human Genome Research Institute
Application Receipt Date(s): December 21, 2011

Economic Studies Ancillary to Completed or Ongoing Health Care Delivery and Financing Pilots, Demonstrations, and Other Experiments (R01)
(RFA-RM-11-023)
NIH Roadmap Initiatives
Application Receipt Date(s): February 08, 2012

Phased Economic Studies Ancillary to Planned Health Care Delivery and Financing Pilots, Demonstrations, and Other Experiments (R21/R33)
(RFA-RM-11-024)
NIH Roadmap Initiatives
Application Receipt Date(s): February 08, 2012

Collaborations with National Centers for Biomedical Computing (R01)
(PAR-12-001)
National Institute of General Medical Sciences
National Cancer Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute of Biomedical Imaging and Bioengineering
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
National Institute of Mental Health
Application Receipt Date(s): Multiple dates, see announcement.

Economic Studies Ancillary to Completed or Ongoing Health Care Delivery and Financing Pilots, Demonstrations and Other Experiments (R01)
(RFA-RM-11-023)
Letters of Intent Receipt Date: January 8, 2012 Application Receipt Date: February 8, 2012

Phased Economic Studies Ancillary to Planned Health Care Delivery and Financing Pilots, Demonstrations, and Other Experiments (R21/R33)
(RFA-RM-11-024)
Letters of Intent Receipt Date: January 8, 2012 Application Receipt Date: February 8, 2012

Academic Research Enhancement Award
(PA-12-006)
Letters of Intent Receipt Dates: Not applicable Application Receipt Dates: Multiple dates, see announcement Standard dates apply
NON-FEDERAL FUNDING AGENCIES

Center for Medicare and Medicaid Innovation
Health Care Innovation Challenge from the CMS Innovation Center is a new initiative designed to test creative ways to deliver high quality medical care and reduce costs across the country. The Challenge will award up to $1 billion in total grants to applicants who will implement the most compelling new ideas to deliver better health, improved care and lower costs to people enrolled in Medicare, Medicaid and CHIP, particularly those with the highest health care needs.

For more information regarding this opportunity visit the website below:

Health Research Funding Opportunity
The National Health Council (NHC) invites researchers with promising projects that have been scored, but not funded by the NIH to submit their abstracts. By registering, you will be able to search for information about organizations that fund research and their requests for abstracts. NIH provided input to NHC in the development of its website, but is otherwise not associated with NHC. However, NIH is encouraged to inform investigators about this NHC website.

For more information regarding these opportunities visit the website below:
http://healthresearchfunding.org/

TSC PUBLICATIONS

Tuberous Sclerosis Complex
Genes, Clinical Features and Therapeutics
David J. Kwiatkowski, Vicky Holets Whittemore, Elizabeth A. Thiele (Eds.)

• A unique comprehensive title on the genetic disorder Tuberous Sclerosis.
• Gives up to date information about the molecular basis, diagnosis and therapies.
• Special focus is placed on novel insights into the signal transduction pathways affected by the disease and genotype phenotype correlations.
• Edited and authored by researchers and clinicians with outstanding international reputation as well as prominent figures in the largest patient advocacy group.

Order your copy online at
www.wiley.com

The SAGE Handbook of Developmental Disorders
Edited by Patricia Howlin King’s College London, Tony Charman Institute of Education, London and Mohammad Ghaziuddin University of Michigan

January 2011 · 592 pages
Hardback (978-1-4129-4486-1) · Price £95.00
Find out more and order online at www.sagepub.co.uk.

September 2011 References


October 2011 References


**November 2011 References**


**CONFERENCES, MEETINGS AND SEMINARS**

**December 2-6, 2011**
**American Epilepsy Society Annual Meeting**
Baltimore, MD
http://www.aesnet.org/go/meetings-and-events/annual-meeting

*December 3, 2011 from 8:00-10:30 pm there will be a TS Alliance Reception (please see the details on page 14)*

**December 3-7, 2011**
**The American Society for Cell Biology 51st Annual Meeting**
Denver, Colorado
http://www.ascb.org/meetings/exhibit.cfm

**December 16, 2011**
**Patient-Specific Induced Pluripotent Stem Cells for the Study of Neurological Diseases**
The New York Academy of Sciences
New York, NY
www.nyas.org/iPSC
February 2-3, 2012
On the Job: Advancing Vocational Opportunities for Persons with Autism Spectrum Disorders
Autism Research Unit, The Hospital for Sick Children
University of Toronto, Toronto ON
http://www.cvent.com/d/QSWD1lly0WEuC8yBlw/wn3h/P1/1Q7%20

March 28-30, 2012
4th Birt-Hogg-Dubé Symposium 2012
Cincinnati, OH
For more information: http://www.bhdsyndrome.org/features-and-events/conferences-and-events/the-fourth-bhd-symposium-2012/

May 5-9, 2012
American Psychiatric Association Annual Meeting
Philadelphia, PA
www.psych.org/annualmeeting

May 18-23, 2012
American Thoracic Society Annual Meeting
San Francisco, CA
http://conference.thoracic.org/2012/

September 6-9, 2012
International TSC Congress
AST-Associazione Sclerosi Tuberosa
Naples, Italy
http://www.sclerosituberosa.it/content/international-tsc-congress

NEWS
TS Alliance Reception at the American Epilepsy Society Meeting
Please join us for a Reception and Brief Presentation on Friday, December 2, 2011 from 8:00-10:30 p.m. at the Hilton Baltimore in the Key Ballroom 2.

Guest Speakers
- Elizabeth Thiele, MD, PhD, Director, The Carol & James Herscot Center for Children and Adults with TSC at Massachusetts General Hospital
- Karen Agricola, FNP-BC, Cincinnati Children’s Hospital Medical Center and Anna Pinto, MD, Children’s Hospital Boston
- E. Martina Bebin, MD, MPA, University of Alabama at Birmingham

Please RSVP to Katie Smith at ksmith@tsalliance.org or 301-562-9890 by Monday, November 28, 2011.

“Emerging Therapeutic Options for Tuberous Sclerosis Complex,” a Local CME Speaker Program Series

Participate in a dinner program* or host a Grand Rounds with a guest speaker at your office or institution. For more information go to www.thecbce.com/tsc.

INFORMATION ABOUT NEW LAM DIAGNOSTIC TEST
A new diagnostic test has been released to measure vascular endothelial growth factor D (VEGF-D).

Vascular endothelial growth factors (VEGF) are proteins that promote the growth of blood vessels and lymphatic vessels. VEGF-D is known to be elevated in blood samples from patients with...
lymphangioleiomyomatosis (LAM) including those with TSC and LAM. There is a high frequency of LAM in women with TSC, and both the TSC Consensus Committee (Roach et al., 1999) and European Respiratory Society (Johnson et al., Eur Respir J 2010; 35) recommend that women with TSC should have a high resolution computerized tomography (HRCT) scan of the chest upon reaching maturity, age 14-26. Measuring levels of VEGF-D in patients with TSC may be a useful test to determine if these patients also have LAM and avoid HRCT scanning in some patients.

Research is ongoing to determine if VEGF-D may be useful for determining the onset and/or progression of LAM in females with TSC, as well as the correlation of VEGF-D levels in the blood and urine with other manifestations of TSC (i.e., growth of renal angiomylipomas). Therefore, females who obtain the VEGF-D test should consult with their physician(s) prior to obtaining the test and regarding results that are obtained as they may or may not indicate the presence of LAM.

The VEGF-D test can now be ordered through the Translational Trials Development and Support Laboratory (TTDSL) at Cincinnati Children’s Hospital. Visit http://www.cincinnatichildrens.org/ttdsl and choose “VEGF-D quantification sample submission form.”

Click here for the recently published European Respiratory Society guidelines for screening females with TSC and LAM. You may also read a PubMed abstract entitled "Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases."

LAM Genome Wide Association Study
Drs. David Kwiatkowski, Lisa Henske and Frank McCormack are initiating a genome wide association study in LAM. Genome wide association studies (GWAS) are done to try to identify genes that predispose to disease development. Sometimes GWAS lead to identification of genes that were completely unexpected from prior knowledge. These doctors hope that this will be the case in LAM, pointing to the importance of a new research direction and possibly even a new therapy for LAM.

They are interested in any patient with a definite diagnosis of LAM, of any age and ethnic group. LAM volunteers will be asked to complete a 1 page questionnaire, and a consent form. Then they will be sent a mailer kit with instructions to put a saliva sample into a special container, to be returned to Boston where it will be processed into DNA. That is all that is required, there will be no costs to participants, or need for blood to be drawn. As part of this study, the genome (DNA constitution) of each LAM subject will be studied in great detail, possibly including determination of the entire sequence of their genome (3 billion nucleotides). Samples will be labeled with a number code so that only the study leaders will be able to connect findings on individual samples with individual LAM patients. DNA results and samples will be shared with other investigators, to the extent possible, to maximize the value of this collection to the LAM research community.

If you are interested and willing to participate in this study, please send an email to Dr. Kwiatkowski at dk@rics.bwh.harvard.edu, or send a letter to him at Brigham and Women’s Hospital, 1 Blackfan Circle Room 6-216, Boston, MA 02115.

**RESOURCES**

**TS Alliance Professional Online Discussion Portal**
In partnership with Veomed, the TS Alliance is pleased to offer a free, private online discussion group/portal for professionals from a variety of fields in TSC research, treatment and education. It is not publicly accessible. Professionals are welcome to join TS Alliance staff members and others who share information via this forum. Complete instructions on joining the discussion group, editing your profile, email settings and other options can be found at http://www.tsalliance.org/documents/TS%20Alliance%20Professional%20Portal%20Login%20Instructions.pdf. For questions, more information, subscription issues, or comments, please contact Katie Smith (ksmith@tsalliance.org).
New National Resource for TSC Drug Testing
The TSC Drug Screening Program is pleased to announce a new resource for drug testing available to all investigators studying TSC. The new **National Resource for TSC Drug Testing** (NRDT) was developed by John V. Frangioni, M.D., Ph.D., Associate Professor of Medicine and Associate Professor of Radiology at Harvard Medical School (www.frangionilab.org), and Fangbing Liu, Ph.D., Instructor in Medicine at Harvard Medical School with funding from the Tuberous Sclerosis Alliance. Housed at the Center for Molecular Imaging (www.centerformolecularimaging.org) of the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School in Boston, MA, the NRDT leverages the resources of the Frangioni laboratory and the Longwood Small Animal Imaging Facility (www.longwoodsaif.org) to provide rapid testing of clinically-viable drug combinations in living animals.

The basis of the NRDT is a new animal model of TSC and lymphangioleiomyomatosis (LAM) that harbors a homozygous mutation in the tsc2 gene. Using a TSC/LAM human cell line (originally developed by Elizabeth Petri Henske, MD and Jane Yu, PhD now at Brigham & Women’s Hospital in Boston together with Rachel Squillace, PhD at The Rothenberg Institute), Dr. Liu stably inserted the gene for the human sodium iodide symporter (NIS). NIS is an unusual membrane transporter, typically found only in the thyroid and stomach, which is capable of concentrating iodide inside cells. Fortunately, NIS will also transport $^{99m}$Tc-pertechnetate, a radioactive tracer compatible with single photon emission computed tomography (SPECT) imaging. Because $^{99m}$Tc-pertechnetate is inexpensive, readily available, and doesn’t have the exposure risks associated with radioactive iodide, it provides an ideal, cost-effective way to detect cells expressing NIS. Once armed with the NIS gene, TSC/LAM cells can be followed anywhere in the body using SPECT/CT, and even tumors as small as 1 mm or less can be quantified non-invasively and repetitively over time.

Drs. Liu and Frangioni then developed an animal model of TSC/LAM that produces reproducible systemic tumors. Using this model, investigators can now assess the effectiveness of drugs and drug combinations against TSC in a rapid manner. The standardized treatment protocol is 2 weeks on-drug and 2 weeks off-drug, with a repeat of 2 weeks on-drug if initially responding tumors re-grow off-drug. At every step, tumors are assessed quantitatively by SPECT/CT for growth or regression.

The NRDT is a no-cost service to all investigators, both academic and industrial, interested in treating TSC and/or LAM with drugs or drug combinations. The investigator needs only to provide the drug(s) in the proper formulation. Priority will be given to drugs that are already available clinically, so that results from the NRDT can be translated rapidly to clinical trials. If interested in utilizing drug testing services of the NRDT, please contact Dr. Frangioni directly at 617-667-0692 or email jfrangio@bidmc.harvard.edu.

TSC1 and TSC2 Variation Databases
The TS Alliance funded the development and ongoing curation of the TSC1 and TSC2 Variation Database. These databases contain the reported variations (mutations and polymorphisms) in the TSC1 and TSC2 genes. The database is curated by Rosemary Ekong, PhD and Sue Povey, PhD at the University College London.

To access the databases, go to:

TSC1 Database: http://www.lovd.nl/TSC1
TSC2 Database: http://www.lovd.nl/TSC2

OrphaNews Europe
OrphaNews Europe is an online newsletter that provides information and updates on new research, clinical studies/trials and general information for individuals interested in rare disease research. To subscribe, go to: http://www.orpha.net/actor/cgi-bin/OAhome.php?Ltr=EuropaNews.

A link to the most recent OrphaNews Europe newsletter: http://www.orpha.net/actor/EuropaNews/2011/111116.html
**TSC CLINICAL TRIALS**

**Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)**

Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with seizures, mental retardation and autism, and exhibiting a high variability in clinical findings both among and within families. Investigators are doing research in order to identify possible neurocognitive benefits from treatment with RAD001 or placebo for a six month period. There may also be potential for improvements in seizure frequency, sleep and autistic behaviors. We hope this trial will lead to a better understanding of TSC and to new forms of treatment, to benefit children and adults with TSC in the future.

Individuals diagnosed with TSC will be asked to participate in this study if they are between the ages of 6 and 21 years of age and have an IQ of greater than or equal to 60. Both males and females will be asked to participate. Additionally, to be eligible for study participation, individuals must have been on the same seizure medication(s), if applicable, for at least 6 months. Individuals must also be able to participate in neuropsychological testing and meet certain medical criteria. They will need to sign an informed consent. If enrolled in the study, participants will have a number of screening tests to help determine if they are eligible for participation in the clinical trial. If eligible for the treatment phase of the trial, they will be asked to take either the study drug or a placebo (pill with no medicine), which is determined by chance.

The study involves about 9 visits over a six month period, as well as follow-up calls with our research nurse. Study visits will vary in length. Screening, three month and six month visits may last up to 8 hours, while all other visits will be less than 2 hours. The study visits include blood draws, laboratory tests and neuropsychological assessments. There is no fee to participate in this study, and there will be no financial compensation for participation in this study. The study drug will be provided at no charge during the study.

After all study data has been analyzed, families will be informed of the overall results. Treatment on this study may or may not improve a child’s learning skills (neurocognition). Future patients may benefit from what is learned.

**For information please contact:**
Kira A. Dies at (617) 919-3009 or by email at kira.dies@childrens.harvard.edu
Melanie Jacobs at (617) 919-3499 or by email at melanie.jacobs@childrens.harvard.edu


**STARS: TS Clinical Research Study**

*This study is currently recruiting participants.* Verified by Penn Epilepsy Center, November 2010

Sabril is an FDA-approved treatment for the following:

- Complex partial seizures in adults
- Infantile spasms, including those due to Tuberous Sclerosis

**What is the STARS: TS Study?**

The STARS: TS Study is a clinical research study. We hope that it will help doctors learn about how safe Sabril is and how well it controls seizures in adult patients with Tuberous Sclerosis.

**Who is eligible to join the study?**

You may be able to join if you:

- Are 18 or older
- Have been diagnosed with tuberous sclerosis
- Have at least 1 seizure per month

What does the study involve?

The study takes 8 months to complete. Participants will take Sabril for 3 months during the study, and may continue to take it after they finish the study if they have a decrease in seizures and don’t have any serious side effects. The study involves 4 visits to the Penn Epilepsy Center and 8 phone calls with the study staff.

If I can get Sabril without being in the study, why join?

Benefits of joining the study include:
- Trying Sabril with frequent safety monitoring
- Access to study doctors and coordinators
- Contributing to the TS community and helping future TS patients
- We hope that this study will establish how safe and effective Sabril is as a treatment for seizures caused by tuberous sclerosis.

For more information or to join the study, call: Penn Epilepsy Center at 215-662-7227.

This research study was approved by the University of Pennsylvania IRB on 11/10/2010.

For a complete list of TSC clinical trials, go to: http://www.tsalliance.org/pages.aspx?content=370
Information can also be found at: http://www.clinicaltrials.gov

**INFORMATION ABOUT TSC**

For information about TSC and the Tuberous Sclerosis Alliance, visit the TS Alliance Web site at: http://www.tsalliance.org or contact the TS Alliance at info@tsalliance.org or by telephone: 1-800-225-6872 or 301-562-9890.